Cite
HARVARD Citation
Alborelli, I. et al. (2020). Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer. Journal of pathology. 250 (1), pp. 19-29. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Alborelli, I. et al. (2020). Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer. Journal of pathology. 250 (1), pp. 19-29. [Online].